India Investment, Stocks, Credit Card and Retail Forum
Investments in Indian Equity and Research => Equity Investments, Fundamental Research and Sectors Review => Topic started by: komal on January 05, 2016, 11:27:40 AM
-
Aurobindo Pharma Key beneficiary of faster USFDA approvals; turnaround in EU - Target 976
Bajaj Finserv Stake sale in Insurance JV offers scope for re-rating - Target 2142
eclerx Reset for growth in the fragmented industry - Target 1615
Indraprastha Gas Clean Fuel Drive – trigger to volume growth - Target 590
Indian Hume Pipe Government’s initiatives in water segment to drive growth - Target 484
Reliance Industries Reliance-Jio – The Next phase of growth - Target 1140